Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.
about
Gene, Stem Cell, and Alternative Therapies for SCA 1Update on the pharmacotherapy of cerebellar and central vestibular disordersPrecision medicine in spinocerebellar ataxias: treatment based on common mechanisms of diseaseCell biology of spinocerebellar ataxiaMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.4-aminopyridine does not enhance flocculus function in tottering, a mouse model of vestibulocerebellar dysfunction and ataxia.Computational neurobiology is a useful tool in translational neurology: the example of ataxiaConsensus paper: management of degenerative cerebellar disorders.Abnormalities in the climbing fiber-Purkinje cell circuitry contribute to neuronal dysfunction in ATXN1[82Q] miceThe role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.Chronic infection of Toxoplasma gondii downregulates miR-132 expression in multiple brain regions in a sex-dependent mannerDystonia and cerebellar degeneration in the leaner mouse mutant.Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2mGlu1 receptor mediates homeostatic control of intrinsic excitability through Ih in cerebellar Purkinje cells.4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6.New roles for the cerebellum in health and disease.Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease.Role of BDNF in central motor structures and motor diseases.Mutational consequences of aberrant ion channels in neurological disorders.Potential therapeutic targets in polyglutamine-mediated diseases.Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research.Peroxisomal Disorders: A Review on Cerebellar Pathologies.Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.Are Type 1 metabotropic glutamate receptors a viable therapeutic target for the treatment of cerebellar ataxia?Cellular and circuit mechanisms underlying spinocerebellar ataxias.Progressive impairment of cerebellar mGluR signalling and its therapeutic potential for cerebellar ataxia in spinocerebellar ataxia type 1 model mice.Cerebellar ataxias: β-III spectrin's interactions suggest common pathogenic pathways.Translating cerebellar Purkinje neuron physiology to progress in dominantly inherited ataxia.IP3 receptor mutations and brain diseases in human and rodents.Aminopyridines for the treatment of neurologic disorders.Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability.Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.Motor and Cerebellar Architectural Abnormalities during the Early Progression of Ataxia in a Mouse Model of SCA1 and How Early Prevention Leads to a Better Outcome Later in Life.Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.High expression of cytochrome b 5 reductase isoform 3/cytochrome b 5 system in the cerebellum and pyramidal neurons of adult rat brain.Polyglutamine spinocerebellar ataxias - from genes to potential treatments.New old drug(s) for spinocerebellar ataxias.Transient cerebellar alterations during development prior to obvious motor phenotype in a mouse model of spinocerebellar ataxia type 6.Ion channel dysfunction in cerebellar ataxia.
P2860
Q26738497-888749D2-6A49-462B-BADE-0BC77A7CA0E2Q26753139-7655F4B0-C1BA-401F-A375-0F52751B97DAQ26764958-26980B32-606A-48C8-9F91-F46C5E75674AQ26829511-67AFCB15-6AA8-4D26-AC9D-7E7C761E4893Q27005950-8EA55988-05A4-45F5-9676-91C1664F95EFQ34603922-D3810794-AC2B-4D7B-BB99-09E395698B3AQ34992022-BDEC6AF8-C0E4-4FFD-AC34-13E037D2C2F2Q35129909-9FE6A408-A8FD-4AA9-8768-067799484025Q35227534-35F0DA1F-9622-4ADD-8992-6CB5EEB1C6BCQ35340099-FCB78C67-C4E5-4763-930E-308B2976446BQ35595804-7AADC47C-2464-415A-ADA7-E372423CEAD5Q35639062-021BB882-AD57-4EA1-91B9-2A739A6CF9F9Q36477656-31F44731-D6C2-47D3-8AF6-33C895E52F14Q37041639-E3F90F4B-98B5-4004-8CC7-15D2CBB9A054Q37067735-6A8BD376-675B-4FFC-B77F-8C0EBA3D3354Q37307036-FD00F2A5-2624-44E6-BF94-0B75B0EBAD03Q37619548-8EBB4C56-E13E-44E0-B34F-A9E9FEE02DDFQ38071648-9E4156E6-419C-47E5-8012-2F9ED6B7A052Q38104654-B95FA627-1122-48DD-B6F3-0B2BAB88D58FQ38239544-0D94760E-7420-4E85-A2D8-BC4DB4A8DE52Q38246221-1BD31DAF-A1B7-4C56-B4E4-66C30E51CE33Q38436175-1EBCE111-58E7-4586-B404-10EBF444E4BBQ38552262-BBC1DB2A-C72D-49EC-844E-7533F5657CC2Q38620925-6AE3ECA5-FC3C-44A8-AE06-56CD954ABF42Q38691240-17914E8F-C686-4C33-AD03-4DFF0B2C176BQ38838873-D3DB6B36-1143-4C12-8948-684638C5F60AQ38839478-51074EA2-7C88-4F6D-99E4-4EADC9C74575Q38915057-F71E5F9C-C547-4EF2-90C7-D2CC05CB858FQ39129263-16BF1C8A-1527-43D2-A231-17EA56DB6B50Q39140608-1EB7A99D-3787-483D-90FE-96417DB7D3FEQ39153784-BFA32B0C-03A8-4FBB-A178-9DE189FDFCFFQ41486765-C0D48FB7-1DDA-48C8-91D8-E92C37F0B8DEQ42264500-B0EBBE99-8388-4B10-B8AC-7423D6DD66A4Q42363213-E77E45DE-3463-4632-AC94-BA78264BC38BQ43445775-2F4A6AEF-BEB2-4457-99FA-46233FAC7A98Q46747223-8D5B94ED-9F04-4D22-805F-391876AF1FB6Q47880472-E3DE759F-33ED-4DC9-8712-ABE55F7A3AE1Q48107041-BEADB074-1783-45D6-91EA-09DEF63E028CQ48108770-D6C82F8D-1CC3-45C3-BE6F-25F93F8000EFQ48505897-EE7145DF-035F-44C9-85A7-9E8CEB41AFA6
P2860
Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Aminopyridines correct early d ...... spinocerebellar ataxia type 1.
@en
Aminopyridines correct early d ...... spinocerebellar ataxia type 1.
@nl
type
label
Aminopyridines correct early d ...... spinocerebellar ataxia type 1.
@en
Aminopyridines correct early d ...... spinocerebellar ataxia type 1.
@nl
prefLabel
Aminopyridines correct early d ...... spinocerebellar ataxia type 1.
@en
Aminopyridines correct early d ...... spinocerebellar ataxia type 1.
@nl
P2093
P50
P1476
Aminopyridines correct early d ...... spinocerebellar ataxia type 1
@en
P2093
David Gall
David Orduz
Guy Cheron
Isabelle Millard
Laurent Servais
Massimo Pandolfo
Raphael Hourez
P304
11795-11807
P356
10.1523/JNEUROSCI.0905-11.2011
P407
P577
2011-08-01T00:00:00Z